Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00400322
Status:
COMPLETED
Last Update Posted:
2021-03-01
First Post:
2006-11-15
Brief Title:
Efficacy and Safety of Valcyte as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus CMV Infection
Sponsor:
Karolinska Institutet
Organization:
Karolinska Institutet
Study Overview
Official Title:
A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte as an add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte R affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue The investigators hypothesis states that CMV infection promotes tumor development and disease progression and inhibits immune responses against the tumor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-002022-29 | EUDRACT_NUMBER | None | None |